$AADI
Aadi Bioscience, Inc. Stock $aadi

$aadi Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024045698 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$7.212M	$5.959M
YoY Change		21.03%	40.38%
Cost Of Revenue		$804.0K	$697.0K
YoY Change		15.35%	17.54%
Gross Profit		$6.408M	$5.262M
YoY Change		21.78%	44.09%
Gross Profit Margin		88.85%	88.3%
Selling, General & Admin		$7.186M	$11.22M
YoY Change		-35.96%	13.17%
% of Gross Profit		112.14%	213.25%
Research & Development		$9.997M	$11.89M
YoY Change		-15.92%	35.53%
% of Gross Profit		156.01%	225.96%
Depreciation & Amortization		$47.00K	$50.00K
YoY Change		-6.0%	316.67%
% of Gross Profit		0.73%	0.95%
Operating Expenses		$17.18M	$23.11M
YoY Change		-25.65%	23.67%
Operating Profit		-$13.41M	-$17.85M
YoY Change		-24.85%	18.71%
Interest Expense		$867.0K	$58.00K
YoY Change		1394.83%	0.0%
% of Operating Profit
Other Income/Expense, Net		$867.0K	$1.547M
YoY Change		-43.96%	175.27%
Pretax Income		-$12.55M	-$16.30M
YoY Change		-23.04%	12.63%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$12.50M	-$16.30M
YoY Change		-23.31%	12.41%
Net Earnings / Revenue		-173.32%	-273.54%
Basic Earnings Per Share		-$0.46	-$0.60
Diluted Earnings Per Share		-$0.46	-$0.60
COMMON SHARES
Basic Shares Outstanding	24.65M shares	24.61M shares	24.52M shares
Diluted Shares Outstanding		27.04M shares	26.95M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.62M	$119.3M
YoY Change	-47.51%	-34.81%
Cash & Equivalents	$30.54M	$68.80M
Short-Term Investments	$32.08M	$50.50M
Other Short-Term Assets	$2.688M	$4.200M
YoY Change	-36.0%	8.78%
Inventory	$5.468M	$3.615M
Prepaid Expenses
Receivables	$6.540M	$5.717M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$77.32M	$132.9M
YoY Change	-41.82%	-30.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.982M	$3.601M
YoY Change	66.12%	687.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.515M	$1.914M
YoY Change	-20.85%	-13.39%
Total Long-Term Assets	$8.383M	$6.775M
YoY Change	23.73%	59.79%
TOTAL ASSETS
Total Short-Term Assets	$77.32M	$132.9M
Total Long-Term Assets	$8.383M	$6.775M
Total Assets	$85.70M	$139.7M
YoY Change	-38.64%	-28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.374M	$2.605M
YoY Change	-47.26%	-33.55%
Accrued Expenses	$14.12M	$11.73M
YoY Change	20.33%	-13.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.81M	$20.52M
YoY Change	-22.93%	14.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$393.0K	$900.0K
YoY Change	-56.33%	-87.33%
Total Long-Term Liabilities	$393.0K	$900.0K
YoY Change	-56.33%	-87.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.81M	$20.52M
Total Long-Term Liabilities	$393.0K	$900.0K
Total Liabilities	$16.83M	$21.46M
YoY Change	-21.59%	-14.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$314.4M	-$252.7M
YoY Change	24.42%	33.49%
Common Stock	$383.2M	$370.9M
YoY Change	3.32%	3.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$68.87M	$118.2M
YoY Change
Total Liabilities & Shareholders Equity	$85.70M	$139.7M
YoY Change	-38.64%	-28.05%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$12.50M	-$16.30M
YoY Change	-23.31%	12.41%
Depreciation, Depletion And Amortization	$47.00K	$50.00K
YoY Change	-6.0%	316.67%
Cash From Operating Activities	-$15.69M	-$11.95M
YoY Change	31.27%	45.82%
INVESTING ACTIVITIES
Capital Expenditures	$188.0K	$1.100M
YoY Change	-82.91%	-1178.43%
Acquisitions
YoY Change
Other Investing Activities	$5.273M	$13.76M
YoY Change	-61.68%	-128.58%
Cash From Investing Activities	$5.085M	$12.67M
YoY Change	-59.87%	-126.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-70.00K
YoY Change	-100.0%	-100.1%
NET CHANGE
Cash From Operating Activities	-15.69M	-11.95M
Cash From Investing Activities	5.085M	12.67M
Cash From Financing Activities	0.000	-70.00K
Net Change In Cash	-10.60M	650.0K
YoY Change	-1731.08%	-95.96%
FREE CASH FLOW
Cash From Operating Activities	-$15.69M	-$11.95M
Capital Expenditures	$188.0K	$1.100M
Free Cash Flow	-$15.88M	-$13.05M
YoY Change	21.65%	61.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Entity File Number EntityFileNumber	001-38560
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	804000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	697000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1267000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	AADI BIOSCIENCE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	61-1547850
	dei	Entity Address Address Line1 EntityAddressAddressLine1	17383 Sunset Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite A250
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90272
	dei	City Area Code CityAreaCode	424
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24647392	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30537000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62888000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	32082000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	77315000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	124586000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1169000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1515000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1866000	usd
CY2024Q3	us-gaap	Assets Assets	85698000	usd
CY2023Q4	us-gaap	Assets Assets	132423000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1374000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5898000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14117000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24614834	shares
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5959000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7186000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11221000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9997000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	20625000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13413000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17849000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	906000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1605000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1547000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26901810	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26901810	shares
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	66000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12546000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	68868000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	158378000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2740000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14306000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	322000	usd
CY2023Q4	aadi	Due To Licensor Payable DueToLicensorPayable	5757000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15813000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26395000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	624000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	16830000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	27228000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24614834	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	383208000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	374129000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	39000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	27000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314381000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268963000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	68868000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	105195000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18744000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18028000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25698000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34204000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11890000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36683000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	67253000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	72247000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-48509000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54219000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3249000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4900000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	867000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3091000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	131419000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3049000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36161000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Address City Or Town EntityAddressCityOrTown	Pacific Palisades
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5982000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4802000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	886000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	833000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Local Phone Number LocalPhoneNumber	744-8055
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	45957000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27041327	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	78791000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	83000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15223000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145986000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001422142
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	AADI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6540000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5488000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	5468000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6427000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2688000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3826000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434000	usd
CY2024Q3	aadi	Due To Licensor Payable DueToLicensorPayable	0	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	393000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24554205	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24554205	shares
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	85698000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132423000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7212000	usd
CY2024Q3	us-gaap	Restructuring Charges RestructuringCharges	2638000	usd
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	2638000	usd
	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2234000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1882000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	23808000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	38000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	58000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	154000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	174000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4723000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12546000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-49496000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	66000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	28000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	99000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12480000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16274000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45406000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49397000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.84
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.84
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27041327	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26946683	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26946683	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27010791	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27010791	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	105195000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3589000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-35000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18289000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	90460000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2839000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	94000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-19000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-14583000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2557000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3054000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	294000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-12000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17971000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	28000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	118196000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-49496000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8985000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8843000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1118000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2650000	usd
	aadi	Non Cash Interest Expense NonCashInterestExpense	38000	usd
	aadi	Non Cash Interest Expense NonCashInterestExpense	58000	usd
	aadi	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	345000	usd
	aadi	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	346000	usd
	us-gaap	Depreciation Depreciation	146000	usd
	us-gaap	Depreciation Depreciation	125000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1052000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3855000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-958000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1040000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2606000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2574000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-367000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-398000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-383000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-375000	usd
	aadi	Increase Decrease In Accounts Payable Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilities	-10365000	usd
	aadi	Increase Decrease In Accounts Payable Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilities	-4947000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	394000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44497000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50019000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1468000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3156000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	36483000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	50542000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	50020000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	133255000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12069000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	79557000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	78000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	94000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	294000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	17000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	126000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	246000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32351000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29784000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62952000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39083000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30601000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	68867000	usd
	us-gaap	Interest Paid Net InterestPaidNet	173000	usd
	us-gaap	Interest Paid Net InterestPaidNet	173000	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	9000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	428000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	122000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314400000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12500000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-16300000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-49500000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	62600000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. In the opinion of management, all adjustments that are considered necessary for fair presentation have been included. The most significant estimates in the Company’s condensed consolidated financial statements relate to gross-to-net accruals, share-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and available-for-sale marketable debt securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. While the Company has not experienced any losses in such deposits, the 2023 failure of Silicon Valley Bank, at which the Company holds cash and cash equivalents in multiple accounts, exposed the Company to credit risk prior to the resolution by the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal Deposit Insurance Corporation in a manner that fully protected all depositors. The Company has not experienced any losses on deposits since inception.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are derived from customers located in the United States. The Company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses on customers’ accounts when deemed necessary. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30537000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62888000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	64000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	64000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30601000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62952000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	32000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	200000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2024Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3547000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4640000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	702000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1366000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1219000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	421000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	5468000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6427000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6398000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5072000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	416000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	270000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5982000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4802000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	47000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	44000	usd
	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2024Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	61845000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	39000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	61884000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	108111000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	108138000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2132000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2504000	usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1652000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1590000	usd
CY2024Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1777000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1250000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3081000	usd
CY2024Q3	aadi	Accrued Clinical Current AccruedClinicalCurrent	1494000	usd
CY2023Q4	aadi	Accrued Clinical Current AccruedClinicalCurrent	1416000	usd
CY2024Q3	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	4196000	usd
CY2023Q4	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	4315000	usd
CY2024Q3	aadi	Accrued Liabilities Other Sales Related Expenses Current AccruedLiabilitiesOtherSalesRelatedExpensesCurrent	941000	usd
CY2023Q4	aadi	Accrued Liabilities Other Sales Related Expenses Current AccruedLiabilitiesOtherSalesRelatedExpensesCurrent	772000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	675000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	628000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14117000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14306000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	886000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1169000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	322000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	624000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	833000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	946000	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	115000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	115000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	345000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	346000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	383000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	375000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	130000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	320000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	231000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	280000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	109000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1070000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	124000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	946000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	322000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	624000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y3M29D
CY2024Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0762
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24614834	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24554205	shares
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2024Q3	aadi	Common Stock Number Of Votes Per Common Share CommonStockNumberOfVotesPerCommonShare	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4579659	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.11
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M13D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1461715	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.87
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	785145	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.79
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5256229	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.99
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	290000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2629899	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.04
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y6M25D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	78000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5256229	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.99
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	290000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14500000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	31000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2557000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3049000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8985000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8843000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29167	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29167	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40000	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.29
	aadi	Number Of Class Of Warrants Exercised NumberOfClassOfWarrantsExercised	0	shares
	aadi	Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod	P6M
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	5700000	usd
CY2023Q4	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	5700000	usd
CY2024Q3	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	4400000	usd
CY2024Q3	aadi	Collaboration And Supply Agreement Expense CollaborationAndSupplyAgreementExpense	300000	usd
CY2023Q3	aadi	Collaboration And Supply Agreement Expense CollaborationAndSupplyAgreementExpense	1000000.0	usd
	aadi	Collaboration And Supply Agreement Expense CollaborationAndSupplyAgreementExpense	100000	usd
	aadi	Collaboration And Supply Agreement Expense CollaborationAndSupplyAgreementExpense	700000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-045698-index-headers.html	Edgar Link	pending
0001628280-24-045698-index.html	Edgar Link	pending
0001628280-24-045698.txt	Edgar Link	pending
0001628280-24-045698-xbrl.zip	Edgar Link	pending
aadi-20240930.htm	Edgar Link	pending
aadi-20240930.xsd	Edgar Link	pending
aadi-20240930xex311.htm	Edgar Link	pending
aadi-20240930xex312.htm	Edgar Link	pending
aadi-20240930xex321.htm	Edgar Link	pending
aadi-20240930xex322.htm	Edgar Link	pending
exhibit102amendmentno03fk.htm	Edgar Link	pending
exhibit103ndesaitransition.htm	Edgar Link	pending
exhibit104litri.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
aadi-20240930_cal.xml	Edgar Link	unprocessable
aadi-20240930_def.xml	Edgar Link	unprocessable
aadi-20240930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aadi-20240930_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aadi-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AADI
Aadi Bioscience, Inc. Stock $aadi

2024 Q4 Form 10-Q Financial Statement

#000162828024045698 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI Aadi Bioscience, Inc. Stock $aadi

2024 Q4 Form 10-Q Financial Statement

#000162828024045698 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI
Aadi Bioscience, Inc. Stock $aadi